These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22778822)

  • 1. GlyT1 - Up from the Ashes. The importance of not condemning a mechanism based on a single chemotype.
    Lindsley C
    ACS Chem Neurosci; 2010 Mar; 1(3):165-6. PubMed ID: 22778822
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
    Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
    Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine specificity.
    Núñez E; Martínez-Maza R; Geerlings A; Aragón C; López-Corcuera B
    Neuropharmacology; 2005 Nov; 49(6):922-34. PubMed ID: 16143353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice.
    Kopec K; Flood DG; Gasior M; McKenna BA; Zuvich E; Schreiber J; Salvino JM; Durkin JT; Ator MA; Marino MJ
    Biochem Pharmacol; 2010 Nov; 80(9):1407-17. PubMed ID: 20637735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
    Perry KW; Falcone JF; Fell MJ; Ryder JW; Yu H; Love PL; Katner J; Gordon KD; Wade MR; Man T; Nomikos GG; Phebus LA; Cauvin AJ; Johnson KW; Jones CK; Hoffmann BJ; Sandusky GE; Walter MW; Porter WJ; Yang L; Merchant KM; Shannon HE; Svensson KA
    Neuropharmacology; 2008 Oct; 55(5):743-54. PubMed ID: 18602930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
    Bridges TM; Williams R; Lindsley CW
    Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors.
    Johnson KW; Clemens-Smith A; Nomikos G; Davis R; Phebus L; Shannon H; Love P; Perry K; Katner J; Bymaster F; Yu H; Hoffman BJ
    Ann N Y Acad Sci; 2003 Nov; 1003():412-4. PubMed ID: 14684475
    [No Abstract]   [Full Text] [Related]  

  • 8. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
    Kinney GG; Sur C; Burno M; Mallorga PJ; Williams JB; Figueroa DJ; Wittmann M; Lemaire W; Conn PJ
    J Neurosci; 2003 Aug; 23(20):7586-91. PubMed ID: 12930797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors.
    Wolkenberg SE; Sur C
    Curr Top Med Chem; 2010; 10(2):170-86. PubMed ID: 20166956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential.
    Alberati D; Moreau JL; Mory R; Pinard E; Wettstein JG
    Pharmacol Biochem Behav; 2010 Dec; 97(2):185-91. PubMed ID: 20678516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New cyclic tetrapeptides from Nonomuraea sp. TA-0426 that inhibit glycine transporter type 1 (GlyT1).
    Terui Y; Chu YW; Li JY; Ando T; Fukunaga T; Aoki T; Toda Y
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6321-3. PubMed ID: 19013063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist.
    Zhang HX; Lyons-Warren A; Thio LL
    Neuropharmacology; 2009; 57(5-6):551-5. PubMed ID: 19619564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into the inhibition of glycine reuptake.
    Shahsavar A; Stohler P; Bourenkov G; Zimmermann I; Siegrist M; Guba W; Pinard E; Sinning S; Seeger MA; Schneider TR; Dawson RJP; Nissen P
    Nature; 2021 Mar; 591(7851):677-681. PubMed ID: 33658720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sarcosine (a Glycine Transport 1 Inhibitor) and Risperidone (an Atypical antipsychotic Drug) on MK-801 Induced Learning and Memory Deficits in Rats.
    Kumar V; Ahmad MA; Najmi AK; Akhtar M
    Drug Res (Stuttg); 2016 Jan; 66(1):11-7. PubMed ID: 25710578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine.
    Mallorga PJ; Williams JB; Jacobson M; Marques R; Chaudhary A; Conn PJ; Pettibone DJ; Sur C
    Neuropharmacology; 2003 Oct; 45(5):585-93. PubMed ID: 12941372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
    Javitt DC
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):468-78. PubMed ID: 19562643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine reuptake inhibition: a promising therapeutic strategy in the treatment of schizophrenia?
    Chue PS; Baker GB
    Future Med Chem; 2013 Sep; 5(13):1475-7. PubMed ID: 24024940
    [No Abstract]   [Full Text] [Related]  

  • 18. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.
    Lindsley CW; Wolkenberg SE; Kinney GG
    Curr Top Med Chem; 2006; 6(17):1883-96. PubMed ID: 17017963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine.
    Zhang HX; Hyrc K; Thio LL
    J Physiol; 2009 Jul; 587(Pt 13):3207-20. PubMed ID: 19433577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.